Peregrine Pharmaceuticals, Inc. Appoints Edward J. Legere, President and Chief Executive Officer
(Business Wire)...the Company plans to move Cotara(TM) into a Phase III clinical trial for the treatment of brain cancer later this year.......rather than surface cancer cells, as a means to attach solid tumors, without causing damage to surrounding healthy tissue.......The Company has three collateral targeting technologies: Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA),...- Apr 06 4:31 PM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/bw/010406/2331.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines